// App-Quantinova.ai

e14531 : PD-L1/L2 tumor profile and long-term survival in mRCC patients after intratumoral administration of a cell-based allogeneic immune enhancer.

Researchers

Presenter

  • Alex Karlsson-Parra

Principal Investigators

  • Maria Lonnemark

  • Anna Laurell

  • Einar Brekkan

  • Anders Magnusson

Medical Centers

  • Department of Immunology, Uppsala University, Uppsala, Sweden

  • Department of Immunology, Uppsala University, Uppsala, Sweden

  • Department of Immunology, Uppsala University, Uppsala, Sweden

  • Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Locations

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • Metastatic Renal Cell Cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Sunitinib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01525017

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved